========================================================
GBM DRUG TARGET EXPLORATION
OrganismCore — Document 81
========================================================

STEP 1: LOADING GBM CACHE
----------------------------------------
Cache shape: (7930, 16)
Columns: ['OLIG2', 'SOX10', 'MBP', 'MOG', 'PLP1', 'PDGFRA', 'SOX2', 'EGFR', 'NES', 'CDX2', 'SPI1', 'KLF4', 'IRF8', 'OLIG1', 'GFAP', 'MKI67']

Cell state distribution:
cell_state
Ambiguous       5010
Normal_Oligo    1586
OPC_like        1334
Name: count, dtype: int64

========================================================
STEP 2: EGFR / PDGFRA CO-ELEVATION
========================================================
OPC-like cells: 1334

EGFR  threshold (p70): 2.0816
PDGFRA threshold (p70): 1.8241

Elevation pattern in OPC-like cells:
  DUAL high (EGFR + PDGFRA):   27 (2.0%)
  EGFR only:                  373 (28.0%)
  PDGFRA only:                373 (28.0%)
  Neither elevated:           561 (42.1%)

EGFR vs PDGFRA correlation:
  Pearson r = -0.4134  p = 3.18e-56
  ANTI-CORRELATED or independent
  Independent attractor inputs

========================================================
STEP 3: OLIG2 LOCK CORRELATION
========================================================
OLIG2 is downstream of EGFR/PDGFRA
in OPCs. If it is the attractor lock,
OLIG2 should be highest in DUAL cells.

OLIG2 expression by elevation group:
  DUAL        : mean=1.0538 ± 0.1113 n=27
  EGFR_only   : mean=0.8480 ± 0.0300 n=373
  PDGFRA_only : mean=0.9589 ± 0.0332 n=373
  NEITHER     : mean=0.6646 ± 0.0263 n=561

DUAL vs NEITHER OLIG2:
  p = 8.28e-04
  OLIG2 significantly higher
  in DUAL co-elevated cells ***
  OLIG2 IS the downstream lock
  Dual EGFR+PDGFRA → OLIG2 → lock

EGFR vs OLIG2:   r=-0.0708 p=9.71e-03
PDGFRA vs OLIG2: r=0.1397 p=3.02e-07

========================================================
STEP 4: ATTRACTOR DEPTH SCORING
========================================================
Deeper attractor = more myelination
genes suppressed + more progenitor
genes elevated simultaneously
Myelination genes: ['MBP', 'MOG', 'PLP1', 'SOX10']
Progenitor genes:  ['EGFR', 'PDGFRA', 'SOX2', 'NES']

Attractor depth by elevation group:
  DUAL        : depth=0.6291 ± 0.0405
  EGFR only   : depth=0.4631 ± 0.0096
  PDGFRA only : depth=0.4583 ± 0.0101
  NEITHER     : depth=0.4483 ± 0.0079

DUAL vs NEITHER depth: p=4.39e-06
  DUAL cells are DEEPER in attractor ***
  Co-elevation = stronger lock
DUAL vs EGFR-only:    p=2.85e-05
DUAL vs PDGFRA-only:  p=3.32e-05

========================================================
STEP 5: MYELINATION SUPPRESSION
BY ELEVATION GROUP
========================================================
If DUAL cells are deepest in attractor
they should have the MOST suppressed
myelination genes — most lost identity

  DUAL (n=27):
    MBP=0.058  MOG=0.347  PLP1=0.116  SOX10=0.000
    avg myelination = 0.1300

  EGFR only (n=373):
    MBP=0.134  MOG=0.346  PLP1=0.341  SOX10=0.019
    avg myelination = 0.2102

  PDGFRA only (n=373):
    MBP=0.111  MOG=0.443  PLP1=0.123  SOX10=0.243
    avg myelination = 0.2302

  NEITHER (n=561):
    MBP=0.061  MOG=0.378  PLP1=0.341  SOX10=0.048
    avg myelination = 0.2071

Interpretation:
Myelination suppression ranking:
(lowest = most suppressed = deepest attractor)
  1. DUAL        : avg=0.1300
  2. NEITHER     : avg=0.2071
  3. EGFR only   : avg=0.2102
  4. PDGFRA only : avg=0.2302

========================================================
STEP 6: DRUG TARGET DERIVATION
FROM ATTRACTOR LOGIC
========================================================
OPC-like cells:          1334
DUAL elevated:           27 (2.0%)
EGFR only elevated:      373 (28.0%)
PDGFRA only elevated:    373 (28.0%)

DRUG TARGET PREDICTIONS:
========================================

TARGET 1: EGFR inhibition
  EGFR elevated +252% in OPC-like
  Mean EGFR in OPC-like: 1.8164
  Relevant to: EGFR-only + DUAL cells
  = 30.0% of OPC-like cells
  Drug class: EGFR inhibitor
  Known drugs: erlotinib, gefitinib,
               osimertinib, cetuximab
  Clinical history: FAILED as
  monotherapy in GBM
  Attractor reason for failure:
  PDGFRA compensates when EGFR blocked

TARGET 2: PDGFRA inhibition
  PDGFRA elevated +83% in OPC-like
  Mean PDGFRA in OPC-like: 1.3827
  Relevant to: PDGFRA-only + DUAL cells
  = 30.0% of OPC-like cells
  Drug class: PDGFR inhibitor
  Known drugs: imatinib, sunitinib,
               ripretinib, avapritinib
  Clinical history: FAILED as
  monotherapy in GBM
  Attractor reason for failure:
  EGFR compensates when PDGFRA blocked

TARGET 3: EGFR + PDGFRA DUAL BLOCKADE
  *** PRIMARY NOVEL PREDICTION ***
  DUAL co-elevated cells: 2.0%
  These are the DEEPEST in attractor
  Both upstream signals active
  Single blockade insufficient —
  the other signal compensates
  Dual blockade removes both inputs
  → attractor has no maintenance signal
  → cells differentiate or die
  Drug combinations to test:
    erlotinib + imatinib
    osimertinib + avapritinib
    cetuximab + sunitinib
  Clinical status: NOT systematically
  tested as attractor-dissolution
  strategy in GBM
  THIS IS THE TESTABLE PREDICTION

TARGET 4: OLIG2 (downstream lock)
  OLIG2 elevated in OPC-like cells
  Downstream of EGFR and PDGFRA
  Transcription factor — harder to drug
  CT-179 OLIG2 inhibitor in preclinical
  Prediction: OLIG2 inhibition would
  dissolve attractor independently of
  upstream RTK signals
  Combination: RTK dual + OLIG2
  = triple attractor dissolution

========================================
WHY PREVIOUS GBM TRIALS FAILED:
========================================
The attractor has multiple inputs.
EGFR alone: blocked → PDGFRA compensates
PDGFRA alone: blocked → EGFR compensates
Both: blocked → OLIG2 may persist
All three: blocked → attractor dissolved

This is the attractor topology
explanation for why GBM is
resistant to single-target therapy.

========================================================
STEP 7: GENERATING FIGURE
========================================================
Figure saved: /Users/ericlawson/cancer/GBM/gbm_saddle_results/gbm_drug_target_figure.png

========================================================
GBM DRUG TARGET EXPLORATION COMPLETE
Results: /Users/ericlawson/cancer/GBM/gbm_saddle_results/
Key output: drug_target_log.txt
Figure:     gbm_drug_target_figure.png
========================================================
